For example, patients with HIF-1α-negative/focally positive and HIF-2α-negative gastric cancers had an average disease-free survival of 81 (95% CI 59−103) months compared with 25 (95% CI 11−39) months for those with invasive edge HIF-1α- and HIF-2α-positive tumours. This evidence concerns the gene HIF1A and gastric cancer.